Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CRL

How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?

Despite underperforming its industry peers over the past year, analysts remain highly bullish on Charles River Laboratories' long-term prospects.

Barchart

Are Wall Street Analysts Bullish on Charles River Laboratories Stock?

Charles River Laboratories has underperformed the S&P 500 over the past 52 weeks, yet Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.

Barchart

City Rail Link opening: ‘The budget for champagne is nil’

Auckland’s smart new metro line won't open until August at the earliest - and, amid claims of a big overspend on the new stations, no costly launch events are planned

Newsroom.co.nz

From analysis to the latest developments in health,
read the most diverse news in one place.

What You Need to Know Ahead of Charles River Laboratories' Earnings Release

Charles River Laboratories will release its first-quarter earnings next month, and analysts anticipate a double-digit profit dip.

Barchart

Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector?

While Charles River Laboratories has underperformed its sector peers recently, analysts remain moderately optimistic about the stock’s prospects.

Barchart

What Are Wall Street Analysts' Target Price for Charles River Laboratories Stock?

Charles River Laboratories has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Barchart

What to Expect From Charles River Laboratories’ Next Quarterly Earnings Report

Charles River Laboratories is scheduled to report its fiscal fourth-quarter results shortly, with analysts forecasting a low–double-digit year-over-year decline in earnings.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Is Charles River Laboratories Stock Underperforming the Dow?

Despite lagging the Dow Jones Industrial Average over the past year, Charles River Laboratories continues to attract cautious optimism from analysts regarding its longer-term outlook.

Barchart

Charles River Laboratories Stock: Is Wall Street Bullish or Bearish?

Charles River Laboratories has continued to underperform the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Barchart

Charles River Beat Expectations But Why Is The Stock Falling?

Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released third-quarter 2025 earnings. It also provided an update on the company’s strategic review.

Benzinga

What to Expect From Charles River Laboratories' Q3 2025 Earnings Report

Charles River Laboratories is all set to release its fiscal third-quarter earnings next month, and analysts project a low double-digit profit decline.

Barchart

Is Charles River Laboratories Stock Underperforming the Nasdaq?

Charles River Laboratories has significantly underperformed the Nasdaq Composite over the past year, yet analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Charles River Laboratories Stock: Analyst Estimates & Ratings

Despite Charles River Laboratories’ weak performance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released second-quarter 2025 earnings.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Here's What to Expect From Charles River Laboratories' Next Earnings Report

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Barchart

Is Charles River Laboratories Stock Underperforming the S&P 500?

Despite Charles River Laboratories' weak performance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain moderately optimistic about its prospects.

Ideal Home

Ideal Home Bathroom Award Winners 2025 – the ultimate bathroom products and designs as chosen by our expert editors

These are the products and design details to keep on your radar this year

Barchart

Do Wall Street Analysts Like Charles River Laboratories Stock?

Charles River Laboratories stock has notably lagged behind the broader market over the past year, yet analysts remain moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Earnings Preview: What To Expect From Charles River Laboratories' Report

Charles River Laboratories is scheduled to announce its first-quarter results next week, with analysts anticipating a single-digit earnings dip.

MarketBeat

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?

Amid market turbulence and policy shifts, do two of the S&P 500’s steepest decliners, DECK and CRL, offer deep value or signal deeper trouble ahead?

Barchart

How Is Charles River Laboratories' Stock Performance Compared to Other Health Care Stocks?

As Charles River Laboratories has underperformed its industry peers recently, analysts remain cautious about the stock’s prospects.

Barchart

Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Charles River Laboratories has lagged behind the broader market over the past year, with Wall Street analysts maintaining a cautious outlook on its future performance.

Barchart

Charles River Laboratories' Quarterly Earnings Preview: What You Need to Know

Charles River Laboratories will release its fourth-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart

Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector?

Charles River Laboratories has underperformed the healthcare sector over the past year, and analysts are cautious about the stock’s prospects.

Barchart

Are Wall Street Analysts Predicting Charles River Stock Will Climb or Sink?

Charles River Laboratories underperformed the broader market over the past year, and Wall Street analysts remain cautious about the stock’s prospects.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Charles River Laboratories

17 stories

MEDP

16 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.